Literature DB >> 25896236

The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.

Carole Fakhry1, Klaus K Andersen2, Jane Christensen2, Nishant Agrawal3, David W Eisele3.   

Abstract

The incidence of oropharyngeal carcinoma, involving palatine and lingual tonsils, is increasing globally. This significant rise is driven by human papillomavirus. Whether palatine tonsillectomy affects risk of diagnosis with oropharyngeal carcinoma is unknown. The association between tonsillectomy and incidence of oropharyngeal carcinoma was explored in the Danish Cancer Registry. The association between tonsillectomy and oropharyngeal carcinoma was analyzed by time since first registration of tonsillectomy. Tonsillectomy was a time-dependent variable. Individuals were censored for death, emigration, or tonsillectomy within incident year of diagnosis. Incidence rate ratios (RR) were estimated by Poisson regression models and adjusted for confounders. Kaplan-Meier survival analyses were compared by the log-rank test, and HRs were estimated by Cox proportional hazards models. From 1977 to 2012, the incidence of tonsillectomies significantly decreased, whereas the incidence of oropharyngeal carcinoma significantly increased. Tonsillectomy was not associated with risk of oropharyngeal carcinoma or malignancies of other anatomic sites, including base of tongue. However, tonsillectomy significantly reduced risk of diagnosis with tonsil carcinoma [RR, 0.40; 95% confidence interval (CI), 0.22-0.70]. The risk of diagnosis with tonsil carcinoma at age <60 years was significantly decreased (RRadj, 0.15; 95% CI, 0.06-0.41) after tonsillectomy. Tonsillectomy within 1 year of diagnosis with tonsil carcinoma was associated with significantly improved overall survival (HR, 0.53; 95% CI, 0.38-0.74). In conclusion, remote history of tonsillectomy reduces the risk of diagnosis with tonsil carcinoma. These data inform risk and benefit of tonsillectomy, a common procedure and design of secondary prevention trials. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25896236      PMCID: PMC4721510          DOI: 10.1158/1940-6207.CAPR-15-0101

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  50 in total

1.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

Authors:  D I Gabrilovich; I F Ciernik; D P Carbone
Journal:  Cell Immunol       Date:  1996-05-25       Impact factor: 4.868

5.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

Authors:  Sebastian Attig; Jörg Hennenlotter; Graham Pawelec; Gerd Klein; Sven D Koch; Hanspeter Pircher; Susan Feyerabend; Dorothee Wernet; Arnulf Stenzl; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 7.  Immune-mediated dormancy: an equilibrium with cancer.

Authors:  Michele W L Teng; Jeremy B Swann; Catherine M Koebel; Robert D Schreiber; Mark J Smyth
Journal:  J Leukoc Biol       Date:  2008-05-30       Impact factor: 4.962

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

10.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

View more
  12 in total

Review 1.  Current Role of Surgery in the Management of Oropharyngeal Cancer.

Authors:  Meghan T Turner; J Kenneth Byrd; Robert L Ferris
Journal:  J Oncol Pract       Date:  2016-11       Impact factor: 3.840

Review 2.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Authors:  Maura L Gillison; Anil K Chaturvedi; William F Anderson; Carole Fakhry
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer.

Authors:  Aimée R Kreimer; Mattias Johansson; Elizabeth L Yanik; Hormuzd A Katki; David P Check; Krystle A Lang Kuhs; Martina Willhauck-Fleckenstein; Dana Holzinger; Allan Hildesheim; Ruth Pfeiffer; Craig Williams; Neal D Freedman; Wen-Yi Huang; Mark P Purdue; Angelika Michel; Michael Pawlita; Paul Brennan; Tim Waterboer
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

4.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

Review 5.  Human papillomavirus and head and neck carcinomas: focus on evidence in the babel of published data.

Authors:  P Morbini; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-08       Impact factor: 2.124

6.  Prevalence and Determinants of Oral Human Papillomavirus Infection in 500 Young Adults from Italy.

Authors:  Valentina Lupato; Dana Holzinger; Daniela Höfler; Anna Menegaldo; Paolo Giorgi Rossi; Annarosa Del Mistro; Maria Cristina Da Mosto; Michael Pawlita; Paolo Boscolo-Rizzo
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

7.  Previous tonsillectomy modifies odds of tonsil and base of tongue cancer.

Authors:  Jose P Zevallos; Angela L Mazul; Nidia Rodriguez; Mark C Weissler; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; D Neil Hayes; Andrew F Olshan
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640

Review 8.  Synchronous bilateral tonsil carcinoma: case presentation and review of the literature.

Authors:  M-N Theodoraki; J A Veit; T K Hoffmann; J Greve
Journal:  Infect Agent Cancer       Date:  2017-06-26       Impact factor: 2.965

9.  Childhood tonsillectomy alters the primary distribution of HPV-related oropharyngeal squamous cell carcinoma.

Authors:  Brannon Altenhofen; Todd A DeWees; Ji W Ahn; Nai C Yeat; Shreya Goddu; Ishita Chen; James S Lewis; Wade L Thorstad; Richard A Chole; Hiram A Gay
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-02-11

10.  HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology.

Authors:  Andrew G Schache; Ned G Powell; Kate S Cuschieri; Max Robinson; Sam Leary; Hisham Mehanna; Davy Rapozo; Anna Long; Heather Cubie; Elizabeth Junor; Hannah Monaghan; Kevin J Harrington; Christopher M Nutting; Ulrike Schick; Andy S Lau; Navdeep Upile; Jon Sheard; Kath Brougham; Catharine M L West; Ken Oguejiofor; Steve Thomas; Andy R Ness; Miranda Pring; Gareth J Thomas; Emma V King; Dennis J McCance; Jacqueline A James; Michael Moran; Phil Sloan; Richard J Shaw; Mererid Evans; Terry M Jones
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.